Streetbeat News

Analyst Ratings

COST

A significant number of investors have taken a bullish stance on Costco Wholesale (NASDAQ:COST), with 63% of recent unusual options trades being bullish and 36% bearish. The trades have targeted a price range of $250.0 to $740.0 for Costco over the last 3 months. The current price of COST is up 0.41% at $548.91. Telsey Advisory Group and Stifel have downgraded their actions to Outperform and Buy respectively, both with a price target of $575. Evercore ISI Group has maintained their Outperform rating with a price target of $595.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 6:32 pm

KRMD

B. Riley has initiated coverage of KORU Medical Systems Inc (NASDAQ:KRMD) with a Buy rating and a price target of $4.50. The company's Freedom Infusion System, which allows patients to self-administer subcutaneous immunoglobulin (SCIg) therapy, is expected to drive a 20% compound annual growth rate in its top-line revenue through 2026. The system is poised to tap into a market opportunity exceeding $2 billion.

Portfolio Pulse from Vandana Singh

September 07, 2023 | 6:27 pm

SLB

Susquehanna analyst Charles P. Minervino reiterated a positive rating on Schlumberger N.V. (NYSE:SLB), raising the price target to $72 from $68. The analyst has slightly tempered his 2024 revenue growth expectation to 15% from 17%, but raised the EBITDA margin estimates to 25.1% from 24.2%. Minervino is bullish on the company's Digital business plan to double its size from $1.5 billion in 2021 to $3 billion by 2025. The analyst also highlighted SLB's partnership with TDA Research to accelerate the development of carbon capture technology.

Portfolio Pulse from Nabaparna Bhattacharya

September 07, 2023 | 6:14 pm

XPOF

B. Riley Securities analyst Jeff Van Sinderen reiterated a Buy rating on Xponential Fitness Inc (XPOF) with a price target of $46. The company provided FY26 operating targets which the analyst believes reflect conservatism by management. XPOF's recent acquisition was BFT in October 2021, and the company is focused on increasing AUV while leveraging support functions at the corporate level. XPOF currently trades at 8x the analyst’s FY24 AEBITDA estimate.

Portfolio Pulse from Shivani Kumaresan

September 07, 2023 | 6:12 pm

UBER

Uber's CEO announced at the Goldman Sachs Conference that the company's delivery business is expected to grow by at least 14% in the second half of the year.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 6:09 pm

ALNY

IONS

RHHBY

Alnylam Pharmaceuticals' KARDIA-1 Phase 2 study of zilebesiran, a drug for hypertension, has met its primary endpoint. The drug is being co-developed with Roche Holdings. The study showed a significant reduction in blood pressure and met key secondary endpoints. The results reaffirm the program's potential and could impact Ionis Pharmaceuticals, which is developing a similar therapeutic. Alnylam's shares are up 0.92%.

Portfolio Pulse from Vandana Singh

September 07, 2023 | 6:07 pm

KURA

Analysts have provided bullish and somewhat bullish ratings for Kura Oncology (NASDAQ:KURA) in the last quarter. The average price target for KURA is $26.31, indicating a potential upside from its current price of $9.77. The average price target has increased by 9.62% over the past month.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 6:00 pm

VVV

Valvoline (NYSE:VVV) has received 2 somewhat bullish and 5 indifferent analyst ratings in the last quarter. The average 12-month price target for the company is $39.29, a 1.78% decrease from the previous average of $40.00. No bearish or bullish ratings were observed.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 6:00 pm

VRT

Over the last quarter, Vertiv Hldgs (NYSE:VRT) has received 10 analyst ratings, with 8 being bullish or somewhat bullish, and 2 indifferent. The company's average 12-month price target has increased by 34.62% from $26.00 to $35.00, with a high of $50.00 and a low of $20.00.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 6:00 pm

PRTG

In the last quarter, Portage Biotech (NASDAQ:PRTG) received 4 bullish analyst ratings, with an average 12-month price target of $10.5, a decrease of 43.24% from the previous average price target of $18.50.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 6:00 pm